The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
Sawai Group Holdings said on June 3 that it has revised its FY2024 financial results announced last month as it has now booked 16.8 billion yen in a litigation provision expense linked to the recent court ruling over its generic…
To read the full story
Related Article
- Towa, Sawai Log H1 Sales Gains, but Overseas Woes and Litigation Drag on Profit
November 21, 2025
- Sawai Follows Fuso to Challenge Remitch Patent Ruling
June 10, 2025
- Fuso Takes Remitch Patent Case to Top Court
June 9, 2025
- Fuso Sets Up 8 Billion Yen Credit Line after Remitch Ruling
June 3, 2025
- Towa, Sawai Log Two-Digit Growth in Operating Profit, but Industry Sees Divide: Tally
May 30, 2025
- Sawai, Fuso Ordered to Pay 20-Plus Billion Yen in Remitch Patent Suit
May 29, 2025
- Fuso Says Toray Jacked Up Damage Claim in Remitch Patent Suit
March 28, 2024
- Extension of Use Patent Term for Remitch Affirmed: Toray
October 27, 2021
- Toray Sues Sawai, Fuso over Use Patent for Remitch OD Tablets
December 20, 2018
BUSINESS
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
- Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025
- Meiji Pharma Sets Up Singapore Unit to Bolster ASEAN Push
December 24, 2025
- Santen Releases VKC Eye Drop Verkazia in China
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…